Pfizer has announced early data in its vaccine trial that indicates an efficacy of 90%! The news could not be better. While the article claims this is early data if you dig down into the details they indicate how many subjects were infected with coronavirus during the study. When the analysis was done, 94 people had been infected. To complete the trial, scientists decided that 164 need to be infected. We are already halfway there. This is the last piece of the puzzle and means we will have an effective vaccine. One caveat is that the Pfizer vaccine is an RNA vaccine. While this makes it easy to manufacture, the vaccine needs to be stored at very low temperatures. Thus transport of the vaccine for distribution will be an issue.
Several other vaccines are in the pipeline and I expect their results to be just as good. Hurray for science.